More News

New bacteria discovered in DNA samples from prostate cancer patients

admin -
University of East Anglia researchers have discovered the genetic blueprints of 18 new bacterial species collected from prostate cancer...

Estuary Biotherapeutics launches with $103m to develop gene therapies for kidney disease

Jim Cornall -
Estuary Biotherapeutics, Inc. has launched with $103m in total committed financing. The financing will support advancement of the company’s two...

Data show reduction in skin epigenetic age and systemic inflammatory biomarkers

Jim Cornall -
Rubedo Life Sciences has revealed new phase 1b clinical findings for RLS-1496, its lead investigational GPX4 modulator. In patients with...

Blood proteins may offer clues to gut health in coeliac disease

Jim Cornall -
Coeliac disease is an autoimmune condition in which the immune system reacts adversely to gluten. Eating gluten causes inflammation...

IMU and UK Biobank to generate world’s most detailed picture of the human immune system

Jim Cornall -
IMU Biosciences has announced a collaboration with UK Biobank to generate large-scale multi-omic immune profiling data from 80,000 blood...

Positive results from schizophrenia study

Jim Cornall -
Tortugas Neuroscience has announced positive phase 2b trial results for obuprazine (TRTL-107), the company’s investigational treatment for schizophrenia. Results from...

Jyong Biotech looks to Texas

Jim Cornall -
Jyong Biotech Ltd. says it plans to establish a potential new manufacturing facility and US operations centre in Texas. The...

New AI tool helps diagnose Ewing sarcoma

Jim Cornall -
A team from the Universitat Politècnica de València (UPV) and the University of Valencia (UV) has developed and validated...

Antibody shows attacking tumour environment also kills cancer cells

Jim Cornall -
Basque biopharmaceutical company Oncomatryx has taken part, together with German research institutions, in a study showing in patient tumour...

FDA clearance leads to influenza trial

Jim Cornall -
Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) has announced that the U.S. Food and Drug Administration (FDA) has granted its...

Plasmonic coating paves way for rapid sepsis diagnosis

Jim Cornall -
A research team has developed a label-free surface-enhanced Raman scattering (SERS) analysis technology that rapidly detects extremely low concentrations...

Mentara Therapeutics launches to tackle dyskinesia

Jim Cornall -
Mentara Therapeutics, a new neuropsychiatry company backed by SPRIM Global Investments, has launched with the acquisition of EM-221, now...

Base to Base biotech podcast 80: Targeting tumour acidity, and developing allosteric therapies

Jim Cornall -
This week, we chat with Ryan Beal, a cancer survivor and founder and CEO of Dyve Biosciences, about tumour...

IQVIA looks to help life sciences companies predict clinical trial outcomes

Jim Cornall -
IQVIA has launched IQVIA Life Science Models to help predict clinical trial outcomes. IQVIA Life Science Models are a suite...

New regulator of muscle regeneration discovered

Jim Cornall -
Skeletal muscles can regenerate following an injury, a process depending on muscle stem cells. In healthy resting muscle, these...

AI system could transform global rabies testing

Jim Cornall -
Rabies virus detection in cell cultures could soon become faster and more accessible, thanks to a world-first AI system...

Life Sciences BC announces seventh annual investor readiness programme

Jim Cornall -
Life Sciences BC (LSBC) has announced the companies selected for its 2027 Investor Readiness Program (IRP). The IRP is...

Mammals produce cyclo-octasulphur to protect cells from lipid damage

Jim Cornall -
Elemental sulphur is well known in microorganisms, plants, and fungi, but whether mammals produce and use elemental sulphur has...

New antibiotic resistance mechanism discovered in superbug Pseudomonas aeruginosa

Jim Cornall -
A joint research team led by Hongbaek Cho of the Department of Biological Sciences at Sungkyunkwan University (SKKU) and...

Preclinical data demonstrate prime-editing correction of pathogenic BRCA1 splice-site mutation

Jim Cornall -
Origin Genomics has announced initial preclinical results from OG-101, its BRCA1 gene-correction research programme. The company screened three prime-editor...

Undecimal Bio launches with $18m to address ‘liver trap’ in siRNA therapeutic delivery

Jim Cornall -
Undecimal Bio, a platform biotechnology company advancing targeted delivery of siRNA therapeutics, has announced an oversubscribed $18m seed financing. The...